Direct pharmacologic comparative studies in relevant cancer cell lines between vorapaxar, atopaxar, PZ-128 and other PAR1-derived pepducins using a set of proteases agonists such as thrombin, MMP-1, MMP-13 and elastase could address this question. The gene discussed is MMP13; the disease is cancer.